On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported by broad-based strength across the biotechnology sector.

On the news front, the company's Chief Scientific Officer recently disclosed progress on its AI-driven drug discovery platform, reinforcing long-term R&D efficiency expectations. The platform covers the full antibody and nucleic acid drug development process, incorporating proprietary AI modules for high-precision structure prediction, immunogenicity assessment, and automated humanization, enabling end-to-end precision from sequence design to clinical stage.

Within the Biotechnology sector, peers rallied in tandem: 3SBIO up 10.54%, SKB Bio up 7.70%, Remegen up 7.67%, Innovent Bio up 3.52%, and BeiGene up 2.17%, reflecting strong sector beta that amplified the individual stock rebound following a cumulative drawdown exceeding 30% from its post-ASCO highs in early June.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)